Yujie Zhao

机构：AbbVie (United States) · ORCID：0000-0002-6702-6526

发表论文 122 篇 · 总被引 1751 次 · h-index 18

代表论文

• Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study (2025 · Signal Transduction and Targeted Therapy · 被引 15)
• Cordycepin alleviates metabolic dysfunction-associated liver disease by restoring mitochondrial homeostasis and reducing oxidative stress via Parkin-mediated mitophagy (2025 · Biochemical Pharmacology · 被引 15)
• Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution (2025 · Current Oncology Reports · 被引 13)
• Unveiling the reaction pathways in the degradation mechanism of enrofloxacin by hydroxyl radicals: A DFT and experiment study (2025 · Journal of Hazardous Materials · 被引 12)
• Intrapleural pressure-controlled piezo-catalytic nanozyme for the inhibition of malignant pleural effusion (2025 · Nature Communications · 被引 11)
• Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer (2025 · Vaccines · 被引 9)